The U.S. government has awarded Moderna $590 million to advance the late-stage development of its mRNA bird flu vaccine, as ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect ...

The version of the virus spreading in North America right now has led to only a few serious cases, but concerns have been ...

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

J.P. Morgan analyst Jessica Fye has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Stay Ahead of the ...

CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.